I'll just throw this here for those who think the vaccines were approved without rigorous study or knowledge, are part of some conspiracy by the powers that be, or whatever. Take it as you will.
To draw an analogy with the ivermectin calls for trials is idiotic.
We have the antigen sequencing for the SARS-CoV-2 spike protein, which enables us to trace its metabolic pathways.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956899/
We have ample data concerning mRna vaccines for anti-viral treatment that goes for over a decade, and trialed for three years.
https://clinicaltrials.gov/ct2/show/NCT01684241
We understand and have extensive data studies about the risk factors involved with the vaccine use, and are conducting studies about the onset of myocarditis in particular.
https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/myo-outcomes.html
We have mitigated the risk factors of mutation by substitution of nucleoside uridine for pseudouridine and N1-methylpseudouridine, which neutralizes immunogenicity. This has been proven in studies since
before the pandemic:
1. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261–279. [
PMC free article] [
PubMed] [
Google Scholar]
2. Pardi N, Hogan MJ, Naradikian MS. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J Exp Med. 2018;215(6):1571–1588. [
PMC free article] [
PubMed] [
Google Scholar]
3. Polack FP, Thomas SJ, Kitchin N. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. [
PMC free article] [
PubMed] [
Google Scholar]
4. Baden LR, El Sahly HM, Essink B. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416. [
PMC free article] [
PubMed] [
Google Scholar]
We have included adjuvants (LPN) to bolster immunological responses in systems with deficiencies.
Pardi N, Hogan MJ, Naradikian MS. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J Exp Med. 2018;215(6):1571–1588.
Long term durability of protection is still being assessed, and will be so in relation to the mutation of the virus.